4. References

  1. Department of Justice. Drug Enforcement Administration. Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Fed Regist. 2014;79(163):49661-82.
  2. DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com.libproxy.uthscsa.edu/. Accessed December 7th, 2021.
  3. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2021. Available at: http://www.clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed December 7th, 2021.
  4. Hydrocodone bitartrate/ acetaminophen oral tablets package insert. H.J. Harkins Company, Inc. September 2018.
  5. Hydrocodone bitartrate/ ibuprofen oral tablets package insert. Amneal Pharmaceuticals of New York, LLC, March 2021.
  6. Hydrocodone polistirex/chlorpheniramine polistirex extended-release suspension (Tussionex® Pennkinetic®) package insert. UCB, Inc., June 2018.
  7. Hydrocodone polistirex/chlorpheniramine polistirex extended-release capsules (TussiCaps®) package insert. Valeant Pharmaceuticals North America LLC, March 2018.
  8. Hydrocodone bitartrate extended-release capsules (Zohydro® ER) package insert. Currax Pharmaceuticals LLC, March 2021.
  9. Hydrocodone bitartrate extended-release tablets (Hysingla® ER) package insert. Purdue Pharma LLP, March 2021.
  10. Hydrocodone bitartrate/ homatropine methylbromide (Hydromet®) oral solution package insert. Actavis Pharma, Inc., August 2020.
  11. U.S. Food and Drug Administration FDA News Release. FDA acts to protect kids from serious risks of opioid ingredients contained in some prescription cough and cold products by revising labeling to limit pediatric use. January 2018.
  12. Naloxone hydrochloride (Narcan®) 4 mg/ 0.1 mL nasal spray package insert. Emergent Devices Inc., March 25, 2021. 
  13. Naloxone hydrochloride (Kloxxado®) 8 mg/ 0.1 mL nasal spray package insert. Hikma Specialty USA Inc., April 2021.
  14. Naloxone hydrochloride (Evzio®) 0.4 mg/ 0.4 mL pre-filled syringe autoinjector package insert. HF Acquisition Co LLC, DBA HealthFirst, February 2020.
  15. Naloxone hydrochloride (LifEMS®) 2 mg/ 2 mL solution for injection convenience kit package insert. Lifsa Drugs LLC, November 2020.
  16. U.S. Food and Drug Administration. FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder. FDA Drug Safety Communication. Published online July 23, 2020. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-health-care-professionals-discuss-naloxone-all-patients-when-prescribing-opioid-pain. Accessed November 19th, 2021.
  17. Texas Pharmacy Association. Texas pharmacist naloxone standing order application. October 2016. Available at: https://www.texaspharmacy.org/page/TXPHARMNALOX. Accessed November 19th, 2021.
  18. Homsi J, Walsh D, Nelson KA, et al. A phase II study of hydrocodone for cough in advanced cancer. Am J Hospice Palliat Med. 2002;19(1):49-56.
  19. Estfan B, LeGrand S. Management of cough in advanced cancer. J Support Oncol. 2004;2(6):523-7.
  20. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part II.  Psychosomatics. 2003;44:515-20.